Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Healthcare Biotechnology
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company's Facility in Israel

GlobeNewswire May 3, 2023

Kamada Issues 2023 CEO Letter to Shareholders

GlobeNewswire March 15, 2023

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

GlobeNewswire March 15, 2023

Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023

GlobeNewswire March 9, 2023

Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company's Facility in Israel

GlobeNewswire January 4, 2023

Kamada Announces Planned Transition of Chief Financial Officer

GlobeNewswire December 19, 2022

Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

GlobeNewswire November 22, 2022

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

GlobeNewswire November 16, 2022

Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT

GlobeNewswire November 7, 2022

Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference

GlobeNewswire October 26, 2022

Kamada Awarded $22 Million Extension of Canadian Supply Tender

GlobeNewswire October 19, 2022

Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance

GlobeNewswire August 17, 2022

Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022

GlobeNewswire August 10, 2022

Kamada Announces Resolution to the Labor Strike at the Company's Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

GlobeNewswire July 15, 2022

Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

GlobeNewswire July 6, 2022

Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market

GlobeNewswire June 15, 2022

Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts

GlobeNewswire June 1, 2022

Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022

GlobeNewswire May 17, 2022

Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification

GlobeNewswire May 17, 2022

Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022

GlobeNewswire May 11, 2022